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ABSTRACT
Background: The thiosemicarbazone CD 02750 (VLX50) was recently reported as 
a hit compound in a phenotype-based drug screen in primary cultures of patient tumor 
cells. We synthesized a copper complex of VLX50, denoted VLX60, and characterized 
its antitumor and mechanistic properties.
Materials and Methods: The cytotoxic effects and mechanistic properties of VLX60 
were investigated in monolayer cultures of multiple human cell lines, in tumor cells 
from patients, in a 3-D spheroid cell culture system and in vivo and were compared 
with those of VLX50.
Results: VLX60 showed ≥ 3-fold higher cytotoxic activity than VLX50 in 2-D 
cultures and, in contrast to VLX50, retained its activity in the presence of additional 
iron. VLX60 was effective against non-proliferative spheroids and against tumor 
xenografts in vivo in a murine model. In contrast to VLX50, gene expression analysis 
demonstrated that genes associated with oxidative stress were considerably enriched 
in cells exposed to VLX60 as was induction of reactive oxygen. VLX60 compromised 
the ubiquitin-proteasome system and was more active in BRAF mutated versus BRAF 
wild-type colon cancer cells.
Conclusions: The cytotoxic effects of the copper thiosemicarbazone VLX60 differ 
from those of VLX50 and shows interesting features as a potential antitumor drug, 
notably against BRAF mutated colorectal cancer.
INTRODUCTION
Thiosemicarbazones have been explored as 
antitumor agents since several decades and a number 
of compounds in this drug family have shown 
promising antitumor activity both in vitro and in vivo 
[1–8]. Triapine (3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone) is the most comprehensively studied 
anticancer thiosemicarbazone and has been described 
as a potent inhibitor of iron containing enzymes such as 
ribonucleotide reductase (RR) and p53R2 [8–10]. The 
inhibitory effect of triapine was previously thought to 
be due to the direct removal of Fe from the enzymes. 
However, more recent data show that redox effects of 
iron complexes of thiosemicarbazones on these enzymes 
and anticancer effects through targeting of a number of 
other molecules, including NDRG1 and top2α, might 
also be important [7, 8, 11, 12]. Triapine and another 
novel thiosemicarbazone, DpC (Dp4cycH4mT), are 
currently in phase I and II clinical trials [13–15] (https://
clinicaltrials.gov/ct2/show/NCT02688101) and other 
thiosemicarbazones, e.g. Dp44mT and Bp44mT, have 
shown potent antitumor activity in tumor xenografts 
in mice [16]. However, clinical trials with triapine 
demonstrated poor activity and side effects such as 
myelosuppression, hypoxia and methemoglobinemia 
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[13–15]. An altered design of the ligand has been proposed 
as a way forward for this class of anticancer drugs [15].
It is well known that the formation of copper 
complexes of mono- and bis-thiosemicarbazones has been 
associated with several fold increased antitumor activity 
in vitro and in vivo [8, 17–22] and it was shown already in 
the 1960s that a powerful antitumor bis-thiosemicarbazone 
required nutrient copper for its activity in a rodent model 
[21, 23]. The success of the platinum anticancer drugs has 
stimulated research on metal-based drugs and the fact that a 
number of copper complexes have shown a broad spectrum 
of antitumor activities has fueled the interest to develop 
copper complexes as anticancer agents [18, 22, 24, 25]. 
Interestingly, copper complexes have also been suggested 
to be able to overcome platinum resistance [17, 18, 22, 
24, 26]. However, little is known about their mechanisms 
of action and most investigations focus on the interaction 
with DNA [22]. Early studies with copper chelates 
of thiosemicarbazones indicated the ability of these 
compounds to induce cell death associated with generation 
of reactive oxygen species (ROS) and depletion of cellular 
glutathione [17, 19], but few papers report on the effects 
on intracellular signal transduction [22]. To the best of our 
knowledge no copper-thiosemicarbazone complex has 
thus far entered clinical trials. However, a phase I clinical 
trial (https://clinicaltrials.gov/ct2/show/NCT00742911) 
of a copper mixture based on co-administration of copper 
gluconate and disulfiram for the treatment of refractory 
solid tumors was recently completed and at least two other 
phase I-II studies, utilizing this copper combination, are 
planned in glioblastoma but not yet recruiting (https://
clinicaltrials.gov/ct2/show/NCT01777919 and https://
clinicaltrials.gov/ct2/show/NCT02715609).
We recently reported on the identification of the 
thiosemicarbazone 3‐(3‐methoxypropyl)‐1‐[[(pyridin‐2‐
yl)methylidene]amino]thiourea (CD 02750, subsequently 
denoted VLX50) (Figure 1A) as a hit in a phenotype-
based drug screen and found it to be active against ovarian 
carcinoma cells both in vitro and in vivo [5]. Confirmed 
by a series of experiments this drug was shown to 
deplete intracellular iron, leading to hypoxia signaling. 
In the present study, our aim was to develop VLX50 
and rationally design a more potent drug with enhanced 
anticancer activity and explore its mechanism of action. 
Therefore, we synthesized a copper complex (Copper(II) 
chloride complex of 3‐(3‐methoxypropyl)‐1‐[[(pyridin‐2‐
yl)methylidene]amino]thiourea) of VLX50 (the copper 
complex subsequently denoted VLX60; Figure 1B) and 
investigated its antitumor and mechanistic properties in 
various models, including xenografts in mice. 
Since in the initial experiments VLX60 was found 
most active against a cell line from colon cancer we 
included colon cancer models able to associate the activity 
to the KRAS and BRAF mutation status, established to 
have predictive and/or prognostic importance in this tumor 
type [27, 28]. Mechanistic properties were explored using 
gene expression analysis of drug exposed tumor cells. 
Since proteasome inhibition has emerged as a putative 
target for copper complexes we also evaluated the effect 
of VLX60 on the ubiquitin-proteasome system (UPS) 
[22, 29–32]. Important general features of cytotoxic 
drugs such as effects on cell proliferation, cell cycle, and 
apoptosis were assessed. 
RESULTS
Drug activity in monolayer cultured cell lines
The cytotoxic effect of VLX50 and VLX60 was 
investigated in 6 different cancer cell lines of various 
origins (Figure 2A–2B).  All cell lines were more sensitive 
to VLX60 than VLX50. The three kidney cancer cell 
lines ACHN, Caki-2 and 786-O as well as the ovarian 
cancer cell line A2780 were highly resistant to VLX50. In 
contrast, all cell lines showed steep drops in cell viability 
well below 10 μM VLX60. For both drugs, the colon 
cancer cell line HCT116 was the most sensitive cell line.
Given the high activity of VLX50 and VLX60 
against the colon cancer cell line HCT116, which is KRAS 
mutated, the activity of these drugs was compared in 
three pairs of colon cancer cell lines with different KRAS 
and BRAF mutation status (Figure 2C–2H and Table 1). 
The parental cells harbor KRAS or BRAF mutations that 
are knocked out (KO) in the KRAS/BRAF sublines. The 
activity of VLX50 was significantly higher in DLD cells 
with wt status of KRAS (DLD KRAS (+/−) compared to 
cells with one mutant allele of the gene (DLD). However, 
KRAS mutation status in HCT116 cells as well as BRAF 
mutation status in RKO cells did not affect the response to 
VLX50. For VLX60 the activity was essentially unaffected 
by KRAS status whereas, interestingly, the RKO cells 
with mutant BRAF were statistically significantly more 
Figure 1: Suggested structural formulae of (A) VLX50 and (B) VLX60.
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than 2-fold more sensitive than the RKO cells with KO 
of mutant BRAF. All six cell lines were more sensitive 
to VLX60 compared with VLX50. IC50 for VLX50 and 
VLX60 were 7.3 μM and 2.3 μM, respectively, in the 
parental HCT116 cells (Figure 2C–2D and Table 1).
In serum free medium, the relative difference 
in efficacy between the drugs remained essentially 
unchanged, indicating that their different potency is 
not due to various protein binding. However, the IC50 
concentrations were approximately 2.5 fold lower than in 
the serum containing standard medium (not shown). 
The activity of VLX60 was not obviously 
associated with p53 status, as shown by the nearly 
identical survival curves irrespective of KO of p53 in 
HCT116 cells (Figure 2I).
The effect of VLX50 and VLX60 was tested against 
a cell line derived from normal colon cells and peripheral 
blood mononuclear cells and compared with the effect 
against HCT116 cells. For both drugs, the colon cancer 
cell line HCT116 was more sensitive than cells from the 
normal cell line, but VLX60 was more active against the 
normal mononuclear cells compared with the tumor cells, 
which was not observed with VLX50 (Online Resource, 
Supplementary Figure 2).
Activity in 3-D spheroid cell culture
VLX50 and VLX60 activity was then examined in a 
multicellular tumor spheroid (MCTS) model, considered 
to better reflect the solid tumor in vivo with respect to drug 
penetration, cell interactions, gene expression, hypoxia 
and nutrient gradients compared with monolayer cultured 
cells [33–35]. Both VLX50 and VLX60 were active in 3 
day-old spheroids, although VLX50 was 4-fold less potent 
(Figure 3). Whereas 6 day-old spheroids were completely 
resistant to VLX50 at up to 50 µM, VLX60 exhibited an 
IC50 of less than 30 µM in this non-proliferative and very 
resistant tumor model. Fluorescence imaging revealed a 
clearly visible effect on 3- and 6 day-old spheroids after 
exposure to VLX60. This is demonstrated in Figure 3, 
where in addition to a lower fluorescence signal also a 
partial dissociation of 6 day-old spheroids is evident after 
exposure to 50 µM VLX60.
Activity in tumor cells from patients
Given the differential activity of both VLX50 and 
VLX60 against the HCT116 colon cancer cell lines vs. 
the other cell lines tested, the activity of these drugs was 
assessed in tumor cells from patients with colorectal cancer 
and compared with cells from patients with acute myeloid 
leukemia (AML), ovarian or kidney cancer (Figure 4A–4B). 
Similar patterns of VLX50 and VLX60 activity were 
demonstrated in the four malignancies with AML cells 
being the most sensitive, followed by ovarian, colon- and 
kidney cancer cells. Importantly, VLX60 showed a ≥  40-
fold higher cytotoxic activity than VLX50 (Figure 4A–4B, 
IC50-values not shown). Thus, although the activity 
pattern in the patient cells did not fully correspond to that 
in the cell lines, the relative effect of VLX60 compared 
to VLX50 was higher in tumor cells from patients than 
in the cell lines. As shown in Table 2 and Figure 4C–4D 
VLX60 exhibited a trend towards enhanced activity against 
both KRAS and BRAF mutated tumor cells from patients 
with colorectal cancer although the difference was not 
statistically significant (KRAS and BRAF mutation status 
was only available in 16 patient samples).
Gene expression analysis
The most substantial finding from the Gene Set 
Enrichment Analysis (GSEA) was that genes associated 
with oxidative stress were substantially enriched in cells 
exposed to VLX60 compared with VLX50 (Figure 5A–5B). 
Among 4 431 a priori defined gene sets, the gene set 
“Chuang oxidative stress response up” exhibited the 
highest enrichment score for VLX60 (Figure 5A). 
Furthermore, in accordance with earlier published results 
Table 1: Antitumor activity of VLX50 and VLX60 in three isogenic cell models of colon cancer
VLX50 VLX60
Cell line IC50 (µM) 95% CI IC50 (µM) 95% CI
HCT116 7.270 5.890, 8.650 2.328 1.265, 3.390
HCT116 KRAS (+/−) 6.186 5.019, 7.352 2.048 0.6730, 3.424
DLD 43.83 19.57, 68.09 1.965 0.9421, 2.988
DLD KRAS (+/−) 12.80 8.729, 16.87 1.963 1.256, 2.671
RKO 18.73 4.980, 32.47 1.015 0.8345, 1.196
RKO BRAF (+/−/−) 15.06 6.519, 23.60 2.449 1.734, 3.163
The parental cells harbor KRAS or BRAF mutations that are knocked out in the KRAS/BRAF sublines. Results are expressed as 
IC50 ±  95% Confidence Interval (CI) and are based on four to eight independent experiments, with duplicate or quadruplicate 
wells for each drug concentration. When statistically significant different IC50-values between the parental cell line and its 
subline are present, it is indicated with an asterisk. *P ≤ 0.05; ***P ≤ 0.001. Concentration-response curves are shown in 
Figure 2C–2H.
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Figure 2: (A–B) Cell survival in the FMCA assay, expressed as survival index of cell lines cultured as monolayers when exposed to 
VLX50 or VLX60 for 72 h. Concentration-response curves are based on two to six independent experiments with duplicate or triplicate 
wells for each concentration. Standard error bars are omitted for clarity. (C–H) Antitumor activity of VLX50 and VLX60 in three isogenic 
cell models of colon cancer. The parental cells harbor KRAS or BRAF mutations that are knocked out in the KRAS/BRAF sublines. 
Concentration-response curves are based on four to eight independent experiments, with duplicate or quadruplicate wells for each drug 
concentration. IC50-values are shown in Table 1. (I) Nearly identical survival curves irrespective of knockout of p53 in HCT116 cells. 
Concentration-response curves (mean ± SEM) are based on two independent experiments with quadruplicate wells for each concentration.
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Figure 3: Cell survival in the FMCA assay, expressed as survival index of cell lines cultured as 3-D spheroids for 
3 or 6 days and then exposed to VLX50 (upper panel) or VLX60 (lower panel) for 72 h. Concentration-response curves 
(mean ± SEM) are based on three to six independent experiments with duplicate or triplicate wells for each concentration. Representative 
fluorescence images of 6 days spheroids exposed to VLX50, VLX60 and control are shown in the right panel. A concentration-response 
curve fitting was not possible for HCT116 GFP 6 days spheroids for VLX50 because of the configuration of the data.
Table 2: Antitumor activity of VLX50 and VLX60 in patient tumor cells from patients with 
colorectal cancer 
VLX50 VLX60
mCRC KRAS and BRAF 
mutation status IC50 (µM) 95% CI IC50 (µM) 95% CI
KRAS wt/BRAF wt 27.8 9.74, 85.8 1.75 0.39, 11.7
KRAS mut 13.5 5.87, 36.3 0.91 0.44, 1.79
BRAF mut 78.5 4.03, N/A 1.00 0.18, 4.65
KRAS and BRAF mutation status was available in 16 colorectal cancer patient samples (KRAS wt/BRAF wt, n = 6; KRAS 
mut, n = 7; BRAF mut, n = 3). Concentration-response curves are shown in Figure 4C–4D.
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[5], the GSEA showed that genes associated with HIF1 
signaling were induced by exposure to VLX50, as opposed 
to VLX60 (Figure 5C–5D). This hypoxia response 
associated with VLX50 treatment has been shown to be 
consistent with iron chelation as mechanism of action [5]. 
Hallmark genes associated with apoptosis were enriched 
in cells exposed to either drug (Figure 5F–5G). Individual 
key genes in the HIF1 signaling pathway and genes 
associated with oxidative stress are shown in Figure 5E. 
Oxidative stress and effects on the ubiquitin-
proteasome system
Exposure to VLX50 for 24 h was not associated 
with ROS formation, as judged by the assessment of the 
superoxide indicator dihydroethidium (DHE) (Figure 6A). 
In contrast, an increase in ROS formation was noted 24 h 
after exposure to VLX60, although less than from the 
same concentration of rotenone, a well-known inducer of 
oxidative stress [36, 37]. ROS induction was also analyzed 
after 2 and 6 h drug exposure. In these experiments an 
increase in ROS by time was demonstrated with 2 µM 
and 10 µM VLX60, whereas there was no ROS induction 
with the same concentrations of VLX50 (not shown). 
Both VLX50 and VLX60 induced early ROS formation 
other than superoxide as judged by the assessment of the 
Oxidative Stress Detection Reagent in HCT116 cells after 
2 h (Figure 6B). The oxidative stress inducer pyocyanin was 
included as positive control and induced ROS formation 
to a lesser degree than the experimental drugs, probably 
explained by a relatively low concentration of pyocyanin 
in a higher concentration of dimethyl-sulfoxide (DMSO) 
(known to inhibit ROS formation). The ROS inhibitor 
N-acetylcysteine (NAC) reversed induction of ROS 
formation in cells treated with VLX50, VLX60 or positive 
control (Figure 6B). Pre-incubation with the ROS inhibitor 
NAC resulted in a right-shift of the concentration-response 
curve for both VLX50 and VLX60 (Figure 6C–6D) whereas 
NAC interacted with CuCl2 to induce cell death (Figure 6E).
Whereas there was no sign of accumulation of the 
UPS substrate UbG76V-YFP after exposure to VLX50 (not 
shown), exposure to VLX60 produced an increase in 
fluorescence after 24 h, similar to bortezomib, a known 
proteasome inhibitor (Figure 6F).
Figure 4: Cell survival in the FMCA assay, expressed as survival index, of patient tumor cells representing the indicated diagnoses when 
exposed to VLX50 (A) or VLX60 (B) for 72 h. Concentration-response curves (mean ± SEM) are based on 7 to 26 samples, with duplicate 
wells for each drug concentration. AML, acute myeloid leukemia. (C–D) Antitumor activity of VLX50 and VLX60 in patient tumor cells 
from patients with colorectal cancer divided by KRAS and BRAF mutation status. IC50-values are shown in Table 2. KRAS and BRAF 
mutation status was available in 16 colorectal cancer patient samples, all investigated for both drugs (KRAS wt/BRAF wt, n = 6; KRAS mut, 
n = 7; BRAF mut, n = 3). Concentration-response curves show means ± SEM.
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Cell cycle, cell proliferation and apoptosis
Cell cycle analysis after 24 h exposure revealed no 
substantial difference between the two compounds; both 
accumulated cells in S and G2/M phases (Figure 6G). After 6 
h drug exposure, VLX50 compared with VLX60 accumulated 
more cells in G1 (Online Resource, Supplementary Figure 
4). Figure 6H confirms the equipotency of the VLX50 and 
VLX60 concentrations chosen for the various experiments 
as they inhibited cell proliferation up to 24 h to the same 
extent. After 24 h the number of cells available for analysis 
decreases, as a sign of cell death.
Both VLX50 and VLX60 induced apoptosis after 
48 h at concentrations close to IC50-values (10 µM 
and 2 µM respectively), as judged by analysis of 
activated caspase-3/7 (Figure 6I–6J). VLX60 at higher 
concentrations (10 and 50 µM) elicited an almost 
immediate activation of caspase-3/7 in contrast to VLX50 
(not shown). However, exposure to VLX60 at these higher 
concentrations was associated with a complete cell death 
already at 24h (not shown).
Antitumor activity of VLX60 in xenograft model
The antitumor activity of VLX60 was explored in 
HCT116 GFP xenograft tumors in mice. Figure 7 shows 
that 0.6 mg/kg/day VLX60 inhibited tumor growth 
(p < 0.05) after 28 days, compared to control. In contrast, 
0.4 mg/kg/day VLX60 did not significantly inhibit tumor 
growth (p > 0.05) after 28 days (Figure 7). VLX60 was 
well tolerated at both doses as assessed from animal 
pattern of gait and body weight. However, 6 animals 
(n = 1 in control group; n = 3 in 0.4 mg/kg/day VLX60 group; 
n = 2 in 0.6 mg/kg/day VLX60 group) were euthanized pre-
term due to a wound or penetrating cavity on the tumor. 
DISCUSSION 
The thiosemicarbazone family of drugs has been 
investigated for several decades after the antitumor 
activity of glyoxal-bis(thiosemicarbazones) was first 
established for Sarcoma 180 in Swiss mice in the 1950s 
[38, 39]. However, side effects, e.g. Triapine induced 
methemoglobinemia, have limited their potential clinical 
efficacy in solid tumors [15] and a rationally designed 
change of a known thiosemicarbazone into a more potent 
drug with a change in mechanism of action that utilizes 
tumor specific vulnerabilities, e.g. ROS and driver 
mutations, would be desirable.
Copper complexes of thiosemicarbazones are known 
for their redox-active properties and the induction of cell 
death by these compounds has been associated with a 
broad spectrum of mechanisms [8, 17–22]. The ability of 
copper chelates of thiosemicarbazones to induce cell death 
associated with generation of reactive oxygen species 
(ROS) and depletion of cellular glutathione was described 
early [17, 19]. However, most investigations of copper 
complexes have focused on the interaction with DNA 
[22]. Little is still known about the mechanisms of action 
and effects on intracellular signal transduction of copper 
complexes [22], although organelles such as the proteasome 
are emerging as new putative targets [22, 29–32]. 
Furthermore, copper complexes have been suggested to be 
able to overcome platinum resistance [17, 18, 22, 24, 26]. 
Although these interesting features of copper complexes of 
thiosemicarbazones have not yet materialized in the clinic 
and no copper complex of a thiosemicarbazone has thus 
far been approved for use against cancer, the interest in the 
development of copper complexes as anticancer agents has 
rapidly grown in the last decade [22].
The results presented here show that the copper 
complex VLX60 has properties worthy of further 
evaluation and is mechanistically different from the original 
compound VLX50. Firstly, VLX60 showed ≥ 3-fold higher 
cytotoxic activity than VLX50 in 2-D cultures from cell 
lines (Figure 2 and Table 1). This difference in activity 
was substantially more pronounced in tumor cells from 
patients (Figure 4). Also, the retained effect in the resistant 
spheroid model (Figure 3), makes VLX60 a promising 
drug candidate for further evaluation in solid tumors since 
three-dimensional cell cultures are thought to better reflect 
the situation in vivo in cancer patients with respect to drug 
interaction, cell-cell interactions, hypoxia and nutrient 
gradients in the tumor [33–35].
Next, we included colon cancer models able to 
associate the activity to the KRAS- and BRAF mutation 
status, established to have predictive and/or prognostic 
importance in this tumor type [27, 28]. The activity of 
VLX60 was significantly higher in RKO cells with mutant 
BRAF (Figure 2H and Table 1). The impact of a drug that 
could selectively target BRAF-mutated colorectal cancer 
would be of great clinical benefit, since BRAF-mutation is 
associated with a poor prognosis and drug resistance [28]. 
Interestingly, VLX60 exhibited a trend towards specific 
activity against both KRAS- and BRAF mutated tumor 
cells from patients with colorectal cancer (Figure 4C–4D 
and Table 2). Thus, further evaluation of VLX60 in BRAF 
mutated colorectal cancer is warranted.
Figure 5: Gene set enrichment analysis. (A and B) Up-regulation of genes associated with oxidative stress. (C and D) Up-regulation of 
genes associated with hypoxia inducible factor 1 (HIF1) signaling. (E) Fold change of key genes in the HIF1 signaling pathway (BNIP3, HK2 
and VEGF) and genes associated with oxidative stress (HMOX, MT1X and MTX1H) as evaluated by the GSEA. (F and G) Up-regulation of 
genes associated with apoptosis. Concentrations used were VLX50 10 µM and VLX60 2 µM. The genes are rank ordered according to their 
relative expression. Enrichment profiles (green lines) are shown of genes (black vertical lines) in each gene set (red = positively correlated; 
blue = negatively correlated). NES, normalized enrichment score. Individual genes included in the a priori defined gene sets are presented 
as supplementary material in the excel-files named “Supplementary Table 1 (VLX50 10 µM) and Supplementary Table 2 (VLX60 2 µM)".
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Figure 6: Oxidative stress, effects on the UPS, cell cycle and apoptosis. (A) Induction of oxidative stress as judged by the 
assessment of the superoxide indicator dihydroethidium (DHE) oxidation in HCT116 cells after 24 h. Results are expressed as percentage of 
control based on six independent experiments, with single or duplicate wells for each drug concentration. Rotenone, a well-known inducer of 
oxidative stress, was included for comparison. (B) Induction of early reactive oxygen species (ROS) formation as judged by the assessment 
of the Oxidative Stress Detection Reagent in HCT116 cells after 2 h. The non-fluorescent probe has a low sensitivity for superoxide and 
reacts directly with a wide range of reactive species, e.g. hydrogen peroxide, peroxynitrite, hydroxyl radicals, nitric oxide and peroxy 
radical, yielding a green fluorescent product. Results are expressed as percentage of control based on three independent experiments, with 
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KRAS and BRAF are both members of the MAPK-
pathway, and it is known that mutational activation of 
this pathway can generate excess ROS [32, 40]. Since 
cancer cells in advanced tumors frequently exhibit high 
oxidative stress, an excessive ROS production through 
pharmacological insults has been proposed as an effective 
strategy to selectively eliminate these cancer cells [32]. As 
discussed below, induction of ROS formation is proposed 
to be important in the mechanism of action of VLX60. 
Thus, the selective effect against BRAF mutated RKO 
cells seen with VLX60 (Figure 2H and Table 1) with a 
trend towards such effect in patient cells with mutated 
KRAS or BRAF (Figure 4D and Table 2) are suggested to 
at least partly be due excessive ROS production in cells 
with altered redox regulatory mechanisms secondary to 
activation of the MAPK-pathway and the fact that BRAF-
mutation status in RKO cells did not affect the response to 
VLX50 (Figure 2G and Table 1) could be due to a lower 
induction of ROS formation by VLX50 compared to 
VLX60 (see below).
Interestingly, gene expression analysis showed 
that genes that are upregulated by KRAS activation 
were upregulated after exposure to VLX50 in contrast 
to VLX60 (Online Resource, Supplementary Figure 5). 
Since superoxide can activate the kinases MEK and ERK 
downstream of KRAS and BRAF [41] and superoxide 
formation was induced by VLX60 in contrast to VLX50 
(Figure 6A), a possible explanation is that ROS induced 
feed-back regulation in the MAPK-pathway is responsible 
for these differences in gene expression patterns. However, 
investigation of the underlying relationships between ROS 
signaling and the impact of KRAS-/BRAF signaling is 
beyond the scope of this study.
Of note, 72 h is a well-established incubation time 
(confluence of HCT116 cells in non-treated control wells 
stabilizes after ~72h) in our lab for assessment of drug 
induced cytotoxic effects and, therefore, the endpoints 
for mechanistic studies should be evaluated at earlier 
time points when the cells are still viable. Thus, early 
assessment of gene expression demonstrated that among 
4 431 a priori defined gene sets, the most substantial 
finding was that genes associated with oxidative stress 
were considerably enriched in cells exposed to VLX60 
(the gene set “Chuang oxidative stress response up” 
exhibited the highest enrichment score), in contrast to 
VLX50 (Figure 5A–5B). VLX60 induced ROS formation 
was confirmed by assessment of the superoxide indicator 
DHE (Figure 6A) and its importance by the reduction 
in cytotoxic activity after pre-incubation with the ROS 
inhibitor NAC (Figure 6D). 
NAC is a precursor to glutathione with antioxidant 
properties but has also been described to act as a reducing 
agent that could activate copper complexes extracellularly 
and induce ROS formation when co-administered [24]. 
However, NAC pre-loading has instead been associated 
with protective effects against ROS generating copper 
complexes [24]. In our study, pre-incubation with NAC 
reduced the cytotoxic activity of VLX60 and therefore the 
interpretation is that a theoretically expected enhanced 
cytotoxic activity induced by a reduction of the copper 
complex extracellularly is outweighed by the antioxidant 
properties of NAC intracellularly. Importantly, in contrast 
to the combination NAC + VLX60, the combination NAC 
+ 100 µM CuCl2 was toxic (Figure 6E) whereas either 
NAC or CuCl2 alone were non-toxic (Figure 6E). This 
is in accordance with previous published results which 
showed that the combination NAC + CuCl2 can induce 
formation of ROS extracellularly and subsequently 
induce oxidative stress in cells through transportation of 
ROS into the cell [42]. Furthermore, because 100 µM 
CuCl2 was non-toxic to cells (Figure 6E), anticancer 
activity by the copper complex VLX60 most probably 
is associated with biological activities of the copper 
complex, not simply from free copper shuttled into cells 
by VLX60. 
A reduction of the cytotoxic activity after pre-
incubation with NAC together with an induction of 
ROS other than superoxide were seen with VLX50 
(Figure 6B–6C) and might be explained by the ability 
of VLX50 to scavenge Cu in the cell culture system 
and induce ROS production through formation of 
VLX60. Also, VLX50 could theoretically utilize 
accumulated copper in cancer cells as a means of 
inducing ROS at levels non-detectable by microarray 
analysis and assessment of DHE but at levels able 
to interfere with intracellular signaling. However, 
since the gene expression results (Figure 5A–5B) 
and the DHE assay (Figure 6A) demonstrate a clear 
quadriplicate wells for each drug concentration. The oxidative stress inducer pyocyanin was included for comparison. The ROS inhibitor 
NAC reverses induction of ROS formation in cells treated with VLX50 or VLX60. (C–D) The ROS inhibitor NAC reverses the effect of 
both VLX50 and VLX60 on HCT116 cells. Concentration-response curves (mean ± SEM) are based on four independent experiments 
with quadruplicate wells for each concentration. (E) The ROS inhibitor NAC interacts with CuCl2 to induce cell death. (F) Accumulation 
of ubiquitin-proteasome system (UPS) substrate UbG76V-YFP induced by VLX60 as evaluated by the increase in fluorescent activity over 
time in MelJuSoUb-YFP melanoma cells transfected with a plasmid encoding the reporter substrate UbG76V-YFP. Results are based on two 
independent experiments, with triplicate wells for each drug concentration. VLX50 showed no accumulation of UPS substrate UbG76V-YFP. 
Bortezomib, a well-known proteasome inhibitor, was included for comparison. (G) Effect of VLX50 and VLX60 on cell cycle in HCT116 
cells. (H) VLX60 inhibits cell proliferation at a lower concentration than VLX50. Results in G-H are based on three to four independent 
experiments, with single or duplicate wells for each drug concentration. (I–J) Induction of apoptosis as judged by the IncuCyte analysis 
of activated caspase-3/7 over time in HCT116 cells. Results are based on two independent experiments, with triplicate wells for each drug 
concentration.
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involvement of ROS in the mechanism of action of 
VLX60 only, the reduced cytotoxic activity observed for 
both drugs after pre-incubation with NAC might also have 
other, yet unknown, explanations.
Overall it is not surprising that VLX60 is 
characterized by ROS production since this has 
previously been described as one of the primary ways 
in which Cu-complexes exert their effects [8, 22, 43, 
44]. Supplementary Figure 3 suggests that VLX50 
binds Cu and once formed, the complex enters the cells. 
Importantly, in concordance with results presented for 
other thiosemicarbazones VLX60 retained its activity in 
the presence of iron, whereas addition of iron impaired the 
cytotoxic activity of VLX50 [4, 5, 8] (Online Resource, 
Supplementary Figure 3). The addition of Cu enhanced 
the cytotoxic activity of both VLX50 and VLX60 (Online 
Resource, Supplementary Figure 3). CuCl2 or FeCl3 were 
nontoxic to HCT116 cells and the addition of CuCl2 
and FeCl3 resulted in no change in the IC50-value of the 
standard drug 5-FU (Online Resource, Supplementary 
Figure 3). Altogether, these data suggests that VLX50 
can react with Fe in contrast to VLX60 and that VLX60 
undergoes reductive dissociation in cells, releasing Cu, 
and then can pick up supplemental Cu to enhance the 
overall accumulation of Cu in cells. Also, the decrease in 
gene expression of genes associated with cation channel 
activity after exposure to VLX60 as opposed to VLX50 
(Online Resource, Supplementary Figure 5) suggests a 
negative regulation secondary to an effective transport of 
copper intracellularly after exposure to VLX60. 
Thiosemicarbazones have recently been described 
as possible ionophores for metal ions [45]. However, 
VLX50 can be considered an ionophore only if VLX60 
is coupled into redox chemistry that reduces Cu(II) to 
Cu(I), reducing its affinity for VLX50 and subsequently 
making it available to react within the cell. Also, since 
thiosemicarbazones have been shown to interact not only 
with copper and iron but also with other metal ions, such 
as zinc [8], it is possible that VLX60 might exchange 
other metal ions with copper intra- or extracellularly. 
The possible interaction of thiosemicarbazones with 
intracellular ions and organelles is indeed an interesting 
subject for further studies. Recently, antitumor activity of 
the copper complex of the thiosemicarbazone Dp44mT 
was coupled to oxidative stress formation through 
accumulation of the redox active copper complex in 
acidic lysosomes [46] and cytotoxicity was greater 
against resistant cells than their nonresistant counterparts 
[3]. Also, since cancer cells have been shown to exhibit 
higher copper levels than normal cells [43, 47], an 
excessive copper load through pharmacological insults 
has been proposed as an effective strategy to selectively 
eliminate these cancer cells. The results presented here 
indicate that iron depletion is of less importance for the 
mechanism of action of VLX60 compared to VLX50 but 
that the interaction with copper is of potential interest for 
Figure 7: Effect of VLX60 in vivo. Data presented show tumor volume over time in mice bearing xenografts of human colon cancer 
cell line HCT116 GFP following intraperitoneal administration of 0.4 or 0.6 mg/kg/day of VLX60. A 100 µl cell suspension containing 5 
× 106 HCT116 GFP cells were injected subcutaneously at the right rear flank of the animals on day -10. At inclusion into the study (day 
0) the majority of the tumors had reached 0.1 cm3 or slightly above and the animals were divided into one of the three study groups (n = 
10 per group). VLX60 was administered daily (0.08 or 0.12 mg/mL in NaCl with 4% DMSO) from day 0 to day 28. Vehicle control (5 
mL/kg of 1% CMC in PBS with 8% DMSO) was administered orally (by gavage, bid) days 0-2 (only one administration was given on 
day 2). **= P = 0.0035 for VLX60 0.6 mg/kg vs control at day 28. × = P = 0.0968 for VLX60 0.4 mg/kg vs control at day 28. CMC = 
carboxymethylcellulose sodium salt. PBS = phosphate buffered saline. DMSO = dimethyl sulfoxide. Bid = twice a day.
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the cytotoxic activity of both VLX50 and VLX60 (Online 
Resource, Supplementary Figure 3). Although data 
suggests that VLX50 can both pick up Fe and compete 
for Cu to form VLX60 whereas VLX60 can probably 
not react with Fe (Online Resource, Supplementary 
Figure 3), a very high and non-physiological extracellular 
concentration of copper would probably need to be 
available for VLX50 to accumulate Cu intracellularly in 
a similar way as VLX60. 
Since proteasome inhibition has emerged as a 
putative target for copper complexes we also evaluated 
the effect of VLX60 on the ubiquitin-proteasome system 
(UPS) [22, 29–32]. In MelJuSoUb-YFP experiments, 
VLX60 exposure showed an increase in fluorescence after 
24 h similar to bortezomib, an established proteasome 
inhibitor (Figure 6F). However, the MelJuSoUb-YFP 
assay indicates compromise of the UPS rather than specific 
proteasome inhibition. Interestingly, proteasome inhibition 
has recently been suggested to represent a valuable target 
strategy in BRAF-mutant colorectal cancer [48].  Thus, 
involvement of BRAF in the mechanism of action of drugs 
that compromise the UPS needs to be further elucidated.
Important general features of cytotoxic drugs such 
as effects on cell cycle, cell proliferation and apoptosis 
were assessed. No substantial difference between the two 
compounds was observed in the cell cycle analysis at 24 
h (Figure 6G). Whereas VLX60 was more potent than 
VLX50, both compounds inhibited cell proliferation in 
HCT116 cells up to 24 h, after which total cell number 
decreased as a sign of cell death (Figure 6H). Both VLX50 
and VLX60 were associated with apoptotic cell death 
as judged by the gene expression analysis and increase 
in fluorescence reporting caspase-3/7 (Figure 6I–6J). 
However, the apoptosis process was faster for VLX60, 
as indicated by the low survival and earlier increase in 
fluorescence reporting caspase-3/7 after exposure to 
higher concentrations of VLX50 and VLX60 (not shown). 
In previous studies, thiosemicarbazones were 
proposed to induce apoptosis through restoration of 
mutated p53 [49, 50]. However, the almost identical 
concentration - response curves regardless of p53-status 
in HCT116 cells in this study argues against a role of p53 
for the effect of VLX60.
Finally, the antitumor activity seen in the murine 
xenograft model (Figure 7) indicates that VLX60 can exert 
activity against malignant cells while sparing normal cells 
in vivo. This presence of a therapeutic window (a drug 
concentration range which is effective against tumors 
while sparing normal tissue) is essential in the treatment 
of cancer patients in the clinic and is supportive for the 
development of VLX60 into an anticancer drug. VLX60 
treatment at the highest concentration was well tolerated 
and opens for testing of higher concentrations and different 
administration schemes to optimize tumor responses.
In conclusion, we demonstrate that VLX60 is 
considerably more potent than VLX50 and that the 
mechanism of action is different although both drugs 
are effective inhibitors of cell proliferation and induce 
apoptotic cell death. Of note, VLX60 is active also in 
non-proliferative models that better reflect the situation in 
cancer patients and cells derived from tumors in patients 
and, importantly, VLX60 exerts antitumor activity in vivo. 
Thus, VLX60 shows interesting properties of potential 
interest for development into a new anticancer drug, 
notably against BRAF mutated colorectal cancer.
MATERIALS AND METHODS
Ethics statement
This investigation was conducted in accordance with 
the ethical standards of the Declaration of Helsinki and 
national and international guidelines and was approved by 
ethical review boards as detailed below. 
Cell lines
The colon cancer cell line HC116 GFP was from 
Anticancer Inc. (San Diego, CA, USA). The kidney cancer 
cell lines ACHN, Caki-2, 786-O, the monocytic cell line 
U937-GTB and the normal colon cell line CCD 841 CoN 
were from American Type Culture Collection (ATCC; 
Manassas, VA, USA). The ovarian cancer cell line A2780 
was obtained from European Collection of Cell Cultures 
(ECACC; Salisbury, UK). Three pairs of colon cancer cell 
lines were used to study the relationship between drug 
effect and KRAS/BRAF mutation status: HCT116, HCT116 
KRAS (+/−) (KO of KRAS mutant allele in heterozygous 
parental cell), RKO, RKO BRAF (+/−/−) (KO of both 
mutant alleles in parental cell), DLD, DLD KRAS (+/−) 
(KO of KRAS mutant allele in heterozygous parental cell) 
were from Horizon Discovery Ltd., Cambridge, UK. All 
purchased cell lines were authenticated by short-term 
repeat analysis performed by the cell banks.
The colon cancer cell line HCT116 p53−/− was 
kindly provided by Prof. Bert Vogelstein (Johns Hopkins 
University, Baltimore, MD, USA). The melanoma cell 
line MelJuSoUb-YFP was kindly provided by Prof. Nico 
Dantuma (Karolinska Institute, Stockholm, Sweden). 
The cell lines were cultured at 37°C in a humidified 
incubator containing 5% CO2 in McCoy´s 5A medium 
(Caki-2, HCT116, HC116 GFP, HCT116 p53−/−, HCT116 
KRAS (+/−), RKO, RKO BRAF (+/−/−), DLD, DLD-
KRAS(+/−)), RPMI1640 medium (A2780, U937-GTB, 
ACHN, 786-O), MEME medium (MelJuSoUb-YFP) or 
EMEM medium (CCD 841 CoN) supplemented with fetal 
calf serum and with change of medium as recommended. 
All media were from Sigma-Aldrich (St. Louis, MO, 
USA) except the EMEM medium which was from ATCC. 
Morphology and growth of cells were monitored on a 
weekly basis and all cell lines were passaged for less than 
6 months.
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Patient tumor cells
Tumor samples were obtained from patients 
diagnosed with acute myeloblastic leukemia (AML), 
ovarian-, colorectal- or kidney cancer by bone marrow/
blood sampling, surgery or diagnostic biopsy.  The 
patient sampling was approved by the regional ethical 
committee, Uppsala University (file Dnr 2007/237). Tumor 
cells from bone marrow/blood (AML) were collected by 
centrifugation and isolated by Ficoll-Paque (GE Healthcare, 
Waukesha, WI, USA) and/or Percoll (GE Healthcare) 
density gradient centrifugation [51]. Samples from solid 
tumors were finely minced and digested with collagenase 
and tumor cells were isolated by Percoll (GE Healthcare) 
density gradient centrifugation [51]. KRAS- and BRAF 
mutation status of colorectal cancer patient samples was 
retrieved from pathology reports in the patient files.
Drugs
VLX50 is a thiosemicarbazone experimental drug 
with iron depletion as main mechanism of action [5]. 
VLX60 is a copper chelate of VLX50. VLX50 was from 
Maybridge (Cambridge, UK) and VLX60 was synthesized 
by author GW. Since VLX60 has VLX50 as precursor 
a synthesis procedure to give access to larger amounts 
of VLX50 was developed. For synthesis and chemical 
characterization of compounds, see supplementary section 1 
and Supplementary Figure 1 (Online Resource). Rotenone, 
CuCl2 and FeCl3 were from Sigma-Aldrich and bortezomib 
from LC Laboratories (Woburn, MA, USA). The 
compounds were dissolved in dimethyl-sulfoxide (DMSO) 
and diluted in either phosphate buffered saline (PBS) or 
distilled water, depending on solubility. N-acetylcysteine 
(NAC) was dissolved in distilled water. Final concentration 
of DMSO in experimental wells was always < 1%. Drug 
concentrations of VLX50 and VLX60 for the experimental 
comparisons were those inducing similar degrees of toxicity 
in HCT116 cells (10 µM VLX50 vs 2 µM VLX60). 
Measurement of cytotoxicity in monolayer 
cultured cell lines and patient tumor cells
The initial cell line experiments were done using 
96-well microplates (Nunc, Roskilde, Denmark) prepared 
as previously described [52] with 20 µl drug solution at 
10× the desired final concentration, using a multipipette or 
the pipetting robot BioMek 2000 (Beckman Coulter, Brea, 
CA, USA). The plates were kept at −70°C and thawed 
immediately prior to further use. On the first day of the 
experiment, 180 μl cell suspension with 5 000–20 000 cells 
(depending on the individual cell line doubling time) were 
seeded into each well in the drug-prepared 96-well plates, 
manually or by using the pipetting robot Precision 2000 
(Bio-Tek Instruments, Winooski, VT, USA), reaching a 
final volume in each well of 200 μl. 
For subsequent experiments in the colon cancer 
cell lines with different KRAS, BRAF or p53 status (see 
above), cell suspension (2 500 cells/well) was added to 
drug-prepared 384-well plates as described below for 
patient samples or cells (2 500/well in 50 µl medium) were 
seeded into 384-well plates and allowed to pre-incubate 
overnight after which drug was added using the liquid 
handling system ECHO® 550 (Labcyte Inc., Sunnyvale, 
CA, USA). This allows for fast transfer of volumes ≥2.5 
nL from source plates into destination wells. In ECHO® 
experiments, source plates were prepared with appropriate 
concentrations of drugs in DMSO and stored in the 
oxygen and moisture free MiniPod™ system (Roylan 
Developments Ltd, Surrey, UK) until further use.  The 
cells were always incubated with drug for 72 h before 
assessment of cell viability (see below).
For tumor cells from patient samples, 45 µl cell 
suspension (5 000 cells/well for solid tumors, 40 000 
cells/well for AML) were seeded into each well in the 
drug-prepared 384-well plates (5 µl/well of drug solution 
at 10x final concentration). All culture plates were 
incubated for 72 h at 37°C in 5% CO2 before assessment 
of cell viability.
Following the 72 h incubation, cell viability was 
assessed using the fluorometric microculture cytotoxicity 
assay (FMCA). The FMCA is based on the conversion 
of fluorescein diacetate (FDA, Sigma-Aldrich, cat. no. 
F7378) to fluorescein by esterases in cells with intact 
plasma membranes [51–53]. Briefly, cells were washed 
in PBS and FDA buffer [52] and FDA solution (0.5 mg 
ml-1 in DMSO) added (50 µl FDA buffer/well, 1 µl FDA 
solution/well). After 50–70 min incubation at 37°C, 
plates were read in the scanning fluorometer FLUOstar 
Optima (BMG Labtech GmbH, Offenburg, Germany). 
The assay was executed in a semi-automated robot system 
as previously described [52]. Cell viability as reported 
from the FMCA is expressed as survival index (SI) and 
is defined as the fluorescence in experimental wells (with 
blank wells subtracted) in per cent of that in control wells, 
with blank wells subtracted. 
Assessment of drug effects in tumor cell 
spheroids
Spheroids were prepared as described [54]. Briefly, 
200 µl cell suspension with 5 000 HCT116 GFP cells were 
seeded into each well of a 96-well NanoCulture® plate 
(SCIVAX USA, Inc., Woburn, MA, USA). The plates 
were incubated at 37°C in 5% CO2. Drug exposure started 
when the spheroids had formed for 3 or 6 days. At start of 
drug exposure, 100μl of medium/well was removed with a 
Multiwasher (DYNEX Technologies, Inc., Chantilly, VA, 
USA), followed by addition of 80 μl fresh medium and 
20 μl drug solution at 10× the final concentration. 
The spheroids were incubated with drugs for 
72 h and then dissociated by addition of 100 µl/well of 
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Accumax (PAA, Pasching, Austria) and incubation at 
37for 30 min followed by mixing with a multipipette 
[54]. After one wash in PBS, cell viability was assessed 
as described above. The plates were also monitored 
in the IncuCyte fluorescence (FLR) system (Essen 
BioScience, Ann Arbor, MI, USA) [54], which allows for 
visual and functional quality control of spheroid growth 
through automated data acquisition of phase contrast and 
fluorescent images within the cell culture incubator prior 
to survival assessment with the FMCA.
VLX 50 and VLX60 mechanistic exploration 
using gene expression analysis
The gene expression analysis of VLX50 and 
VLX60 was performed according to the original protocol, 
as previously described [55]. Briefly, HCT116 cells (0.3 
x 106 cells/well) were seeded into each well in 6-well 
plates and allowed to attach for 24 h. VLX50, VLX60 
or vehicle control (DMSO) were then added at a final 
concentration of 10 µM (VLX50) or 2 µM (VLX60). 
Cells were incubated with drug or vehicle control for 6 
h and then washed with PBS. RNA was isolated using 
RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA 
concentration and quality were measured using an ND 
1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) and Bioanalyzer system (Agilent 
Technologies Inc., Palo Alto, CA, USA), respectively. 
Starting from 2 µg of total RNA from each sample, 
gene expression analysis was performed using Human 
Genome U133 Plus 2.0 Arrays according to the GeneChip 
Expression Analysis Technical Manual (Rev. nr 5, 
Affymetrix Inc., Santa Clara, CA, USA). Raw data was 
MAS5 normalized.
Gene expression ratios for drug vs. vehicle 
exposed cells were calculated to generate a list of 
regulated genes, based on the RMA normalized data, 
and this list was filtrated using flags from the MAS5 
normalization. Only probes with present call in both 
drug treated and vehicle control lists were used in the 
Gene Set Enrichment Analysis (GSEA), as described 
previously [56]. Average fold change was used as rank 
metric for drug vs. vehicle exposed cells to establish 
the rank lists. The rank lists were compared with a 
priori defined and curated gene sets with the purpose to 
find out whether these a priori defined gene sets were 
significantly enriched toward the upper or lower end 
of the ranked lists. The p-value refers to the nominal 
p-value after 1000 permutations. Individual genes 
included in the a priori defined gene sets are presented 
as supplementary material in the form of excel-files 
named “Supplementary Table 1 (VLX50 10 µM)” and 
“Supplementary Table 2 (VLX60 2 µM)”. Raw and 
normalized expression data have been deposited at Gene 
Expression Omnibus (https://www.ncbi.nlm.nih.gov/
geo/) with accession number GSE86309.
Assessment of oxidative stress
I. HCT116 cells (5 000 – 20 000/well) were 
seeded into 96-well plates and allowed to pre-incubate 
overnight.  Drugs were added the next day and the 
commercially available Cellomics® Oxidative Stress I 
Kit (Thermo Fisher Scientific, Gothenburg, Sweden) was 
used to study oxidative stress. The assay was analyzed in 
the fluorescence microscope Arrayscan II high content 
screening system (Cellomics Inc., Pittsburgh, PA, USA). 
Fluorescence provides a readout of the superoxide indicator 
dihydroethidium (DHE) oxidation of ROS generation. II. 
Induction of other ROS than superoxide was assessed 
with Oxidative Stress Detection Reagent (Green) and 
the positive control pyocyanin from the Cellular ROS/
Superoxide Detection Assay Kit (Abcam, Cambridge, 
UK). HCT116 cells (2500/well) were seeded into 384-well 
plates and allowed to pre-incubate overnight. NAC (5 mM) 
was added 30 min before drug. Drugs and Oxidative Stress 
Detection Reagent (Green) were added using the liquid 
handling system ECHO® 550. The plates were incubated for 
2 h, centrifuged and washed twice in PBS and then analyzed 
in the IncuCyte ZOOM Live-Cell Analysis System (Essen 
BioScience, Ann Arbor, MI, USA). Fluorescence provides 
a readout of the probe which has a low sensitivity for 
superoxide and reacts directly with a wide range of reactive 
species, e.g. hydrogen peroxide, peroxynitrite, hydroxyl 
radicals, nitric oxide and peroxy radical, yielding a green 
fluorescent product. III. In the ROS inhibitor experiments 
measurement of cytotoxicity was performed in 384-well 
plates (2 500 cells/well) as described above (with FMCA) 
with 5 mM NAC added 30 min before drug.
Cell cycle analysis
HCT116 cells (0.3 × 106 cells/well) were seeded 
into each well in 6-well plates and allowed to attach for 
24 h. VLX50, VLX60 or vehicle control (DMSO) were 
then added at a final concentration of 10 µM (VLX50) 
or 2 µM (VLX60). Cells were incubated with drug or 
vehicle control for 0–72h and the commercially available 
kit Two-step cell cycle analysis (Application note No. 
0254. Rev. 1.1; ChemoMetec, Allerod, Denmark) was 
used to study the cell cycle. The assay was analyzed in the 
NucleoCounter® NC-250™ (ChemoMetec).
Assessment of the effects on the ubiquitin-
proteasome system and apoptosis
The IncuCyte FLR system (Essen BioScience) was 
used to study effects on the ubiquitin-proteasome system 
(UPS) and apoptosis. MelJuSoUb-YFP (yellow fluorescent 
protein) is a melanoma cell line transfected with a plasmid 
encoding the reporter substrate UbG76V-YFP. Proteasome 
inhibition, endoplasmic reticulum (ER) stress or other 
stress factors compromise the UPS and cause accumulation 
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of the UPS substrate UbG76V-YFP. This accumulation results 
in an increase in cellular fluorescence [57]. MelJuSoUb-
YFP cells were seeded at a concentration of 6 000 cells/90 
µl MEME-medium/well into 96-well plates and allowed 
to pre-incubate overnight after which 10 µl drug solution 
at 10x the final concentration were added to each well. 
The plates were monitored in the IncuCyte for 48 h and 
the IncuCyte FLR system software was used to calculate 
object count per mm2 based on fluorescence.
For assessment of apoptosis, HCT116 cells were 
seeded at a concentration of 10 000 cells/80 µl McCoy´s 
medium/well into 96-well plates and allowed to pre-
incubate overnight followed by addition of 10 µl/well of 
Essen CellPlayerTM Kinetic Caspase-3/7 Apoptosis reagent 
drug (Essen) and then immediately 10 µl/well of drug 
at 10× the final concentration, reaching a final volume 
of 100µl/well. The final concentration of the kinetic 
apoptosis reagent was 2.5 µM. The plates were monitored 
in the IncuCyte for 48 h and the IncuCyte FLR system 
software was used to calculate object count per mm2 based 
on fluorescence. The assay provides a kinetic readout of 
apoptotic signaling based on activation of Caspase-3/7.
Assessment of drug effects in tumor xenografts
Mice experiments received ethics approval by 
regional animal experimental ethics committee in Stockholm 
(North), approval number N37/15 and N188/15. The age 
of the mice were 7 weeks at arrival and acclimatisation 
was a minimum of five days before commencement of 
the experiment. Five animals per cage were maintained 
in individually ventilated cages (type IVC2). Temperature 
was kept at 21–22°C, humidity was 50–60% and a 12 h 
light, 12 h dark cycle was applied. Autoclaved tap water 
was available ad libitum in water bottles and the animals 
received R70, irradiated, diet (Lantmännen, Sweden). 
Female NMRI nu/nu mice (Crl:NMRI-Foxn1nu) from 
Charles River, Germany, were injected subcutaneously at the 
right flank with 5 × 106 HCT116 GFP cells 10 days before 
randomization into treatment groups. When the majority of 
the tumors had reached 0.1 cm3 (day 0) the animals were 
randomly assigned into treatment groups (n = 10 animals 
per group) and administered a daily intraperitoneal dose 
(0.4 mg/kg or 0.6 mg/kg; 0.08 or 0.12 mg/mL respectively 
in NaCl with 4% DMSO) of VLX60 for 28 days or control 
vehicle (administered by oral gavage with 5 mL/kg of 1% 
carboxymethylcellulose sodium salt (CMC) in PBS with 8% 
DMSO twice daily from day 0–2; only one administration 
day 2). The length and width of each tumor was measured 
with the use of a caliper twice weekly and tumor volume 
was calculated by the formula length (cm) × width (cm) 
× width (cm) × 0.44. Body weight was recorded at the start 
and at the end of the study and the animals were checked 
daily for change in activity and appearance as signs of a 
change in general health status.
Data analysis and presentation
For in vitro studies IC50 values, i.e. the concentration 
resulting in a SI-value of 50%, were obtained using non-
linear regression in GraphPad Prism 5 (GraphPad Software 
Inc., CA, USA). Results are presented as means ± SEM 
or means ± 95% Confidence Interval (CI) for the number 
of experiments indicated. Comparisons between mutated- 
and parental cell lines were done with unpaired Student´s 
t-test. GraphPad Prism 5 was used for result calculations, 
statistical inference and graphical presentation. 
For in vivo studies the mean with SEM was 
calculated for tumour volumes recorded during the 
experiment. At start, all groups comprised 10 animals 
(N = 10), but along the study a few animals were 
euthanized due to reduced health status. Tumour data 
from animals terminated pre-term was carried forward in 
the statistical analysis (one animal in the 0.4 mg/kg/day 
group was euthanized at day 3 due to abnormal gait and 
was excluded from the analysis). Differences in tumour 
volume between the groups were calculated using repeated 
measures (from day 0 to 28) two-way ANOVA followed by 
Tukey´s multiple comparisons test using GraphPad Prism 
7. Comparisons were made between Group 1 (Vehicle) vs 
Group 2 (Vehicle + VLX60 0.4 mg/kg/day) and Group 1 
(Vehicle) vs Group 3 (VLX60 0.6 mg/kg/day). A p-value 
of < 0.05 was used to indicate statistical significance.
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